Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer94, 153–156 (2001).
   PubMed Web of Science ®Google Scholar
• Gibson MK, Forastiere AA. Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art. Curr. Opin. Oncol.16(3), 220–224 (2004).
   PubMed Web of Science ®Google Scholar
• Licitra L, Felip E. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.20(Suppl. 4), 121–122 (2009).
   PubMedGoogle Scholar
• Curtin H, Ishwararn H, Mancuso H, Dalley B, Caudry D, McNeil B. Comparison of CT and MRI imaging in staging of neck metastases. Radiology207, 123–130 (1998).
   PubMed Web of Science ®Google Scholar
• Ng SH, Yen TC, Liao CT et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J. Nucl. Med.46, 1136–1143 (2005).
   PubMed Web of Science ®Google Scholar
• Hannah A, Scott AM, Tochon-Danguy H et al. Evaluation of 18F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann. Surg.236, 208–217 (2002).
   PubMed Web of Science ®Google Scholar
• Ng SH, Yen TC, Chang JCT et al. Prospective study of [18F] fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J. Clin. Oncol.24, 4371–4376 (2006).
   PubMed Web of Science ®Google Scholar
• Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J. Natl Cancer Inst.100, 712–720 (2008).
   PubMedGoogle Scholar
• Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med.350, 1937–1944 (2004).
   PubMed Web of Science ®Google Scholar
• Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med.350, 1945–1952 (2004).
   PubMed Web of Science ®Google Scholar
• Bernier J, Cooper JS, Pajak TF et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (9501). Head Neck843–849 (2005).
   PubMedGoogle Scholar
• Kies MS, Harris J, Rotman MZ et al. Phase II randomized trial of postoperative chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). Proceedings of the 51st Annual ASTRO Meeting. Int. J. Radiat. Oncol. Biol. Phys.75(3), S15 (2009) (Abstract 29).
   Google Scholar
• Pignon JP, Bourhis J, Domenge C, Designe L. Meta-analysis of chemotherapy in head and neck squamous cell carcinoma. On behalf of the MACH-NC collaborative group. Lancet355, 949–955 (2000).
   PubMed Web of Science ®Google Scholar
• Machtay M, Moughan J, Trotti A et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J. Clin. Oncol.26(21), 3582–3589 (2008).
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Saxton JP, Rybicki LA et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J. Clin. Oncol.24, 1064–1071 (2006).
   PubMedGoogle Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N. Engl. J. Med.354, 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: mature efficacy results of a Phase III trial. Lancet Oncol. (In press).
   Google Scholar
• Giralt J, Trigo JM, Nuyts S et al. A Phase 2 randomized trial of radiotherapy (RT) plus panitumumab compared to chemoradiotherapy in patients with unresected, locally advanced squamous cell carcinoma of the head and neck: interim pooled safety analyses. ECCO 15–34th ESMO. Eur. J. Cancer14(Suppl. 1), (2009).
   Google Scholar
• Quon H, Langer CJ, Lee J et al. E3303: a Phase II study of cetuximab (C225) in combination with cisplatin (DDP) and definitive radiation (XRT) in unresectable squamous cell carcinoma of the head and neck (U-SCCHN). Int. J. Radiat. Oncol. Biol. Phys.75(3), S15 Proceedings ASTRO 51 (2009).
   Google Scholar
• Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol.23, 8636–8645 (2005).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med.357, 1695–1704 (2007).
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med.357, 1705–1715 (2007).
   PubMed Web of Science ®Google Scholar
• Lorch J, Haddad RI, Fasciano J et al. Long term (five-year) results of Tax324: a Phase III trial of sequential therapy comparing TPF with PF in patients with locally advanced squamous cell cancer of the head and neck. Proceedings of ECCO15-ESMO34. Eur. J. Cancer7, (2009) (Abstract 470).
   Google Scholar
• Grégoire V, De Neve W, Eisbruch A, Lee N, Van den Weyngaert D, Van Gestel D. Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist12, 555–564 (2007).
   PubMed Web of Science ®Google Scholar
• Eisbruch A, Harris J, Garden AS et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp.2009.04.011(2009) (Epub ahead of print).
   Google Scholar
• Pacholke HD, Amdur RJ, Morris CG et al. Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am. J. Clin. Oncol.28, 351–358 (2005).
   PubMedGoogle Scholar
• Nutting C, A’Hern R, Rogers MS et al. First results of a Phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). J. Clin. Oncol.27, 18s (2009).
   Google Scholar
• Pow EH, Kwong DL, McMillan AS et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int. J. Radiat. Oncol. Biol. Phys.66, 981–991 (2006).
   PubMed Web of Science ®Google Scholar
• Peters LJ, O’Sullivan B, Giralt J et al. Radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer – results from TROG 02.02. J. Clin. Oncol. (2010) (In press).
   Google Scholar
• Gillison ML, Harris J, Westra W et al. Survival outcomes by tumor human papillomavirus (HPV) status in stage III–IV oropharyngeal cancer (OPC) in RTOG 0129. Proc. Am. Soc. Clin. Oncol.27, (2009) (Abstract 6003).
   PubMedGoogle Scholar
• Lassen P, Eriksen JG, Hamilton-Dutoit S et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J. Clin. Oncol.27, 1992–1998 (2009).
   PubMed Web of Science ®Google Scholar
• Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus – positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl Cancer. Inst.100, 261–269 (2008).
   PubMed Web of Science ®Google Scholar
• Licitra L, Perrone F, Bossi P et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J. Clin. Oncol.24, 5630–5636 (2006).
   PubMed Web of Science ®Google Scholar
• Kumar B, Cordell KG, Lee JS et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol.26, 3128–3137 (2008).
   PubMed Web of Science ®Google Scholar
• Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin. Radiat. Oncol.19, 63–68 (2009).
   PubMed Web of Science ®Google Scholar